More about High-Yield Cash Accounts with M1
Brokerage Accounts
Retirement Accounts
Other Accounts
Quotes are delayed by 15 minutes.
1D
1W
1M
3M
6M
YTD
1Y
2Y
5Y
ALL
Market cap
$1.31B
EPS
-0.23
P/E ratio
--
Price to sales
2.69
Dividend yield
--
Beta
1.092601
Previous close
$3.96
Today's open
$3.96
Day's range
$3.90 - $4.18
52 week range
$2.23 - $6.51
show more
CEO
Michael E. Castagna
Employees
592
Headquarters
Danbury, CT
Exchange
NASDAQ Global Market
Shares outstanding
321640118
Issue type
Common Stock
Healthcare
Biotechnology & Life Sciences
MannKind Sees Profitability Next Year as FUROSCIX Conversion Beats Expectations
MannKind NASDAQ: MNKD is focusing on the launch of its FUROSCIX ReadyFlow autoinjector, pediatric AFREZZA and the development of inhaled nintedanib, CEO Michael Castagna said at the UBS Biopharma Conference in London.
MarketBeat • 14 hours ago

MannKind Sees Q4 Profit and Record Revenue as Drug Launches Gain Traction
MannKind NASDAQ: MNKD expects to be profitable and report record revenue in the fourth quarter as it builds on the launch of FUROSCIX ReadyFlow and the pediatric approval of inhaled insulin Afrezza, CEO Michael Castagna said at the Jefferies 2026 Global Healthcare Conference.
MarketBeat • 7 hours ago

MannKind Corporation (MNKD) Presents at UBS Global Biopharma Conference 2026 Transcript
MannKind Corporation (MNKD) Presents at UBS Global Biopharma Conference 2026 Transcript
Seeking Alpha • Nov 17, 2026

MannKind's ReadyFlow Launch Keeps The Bull Case Alive
MNKD's ReadyFlow could widen Furoscix's reach into more outpatient settings, which I consider a promising value driver in the long run. Also, their pediatric launch expands Afrezza's market. The main caveat to this is that it requires an added lung-function screening for patients. Aside from that, Tyvaso DPI royalties remain vital for MNKD, but fortunately, they're likely to keep growing as well in the near term.
Seeking Alpha • Nov 12, 2026

MannKind to Participate in Upcoming Investor Conferences
DANBURY, Conn. and WESTLAKE VILLAGE, Calif.
GlobeNewsWire • Nov 10, 2026

MannKind Q3 Earnings Call Highlights
MannKind NASDAQ: MNKD expects to return to profitability in the fourth quarter after reporting higher third-quarter revenue and a net loss, as the company's FUROSCIX ReadyFlow and pediatric Afrezza launches gain traction.
MarketBeat • Nov 6, 2026

MannKind Corporation (MNKD) Q3 2026 Earnings Call Transcript
MannKind Corporation (MNKD) Q3 2026 Earnings Call Transcript
Seeking Alpha • Nov 6, 2026

MannKind (MNKD) Reports Q3 Loss, Misses Revenue Estimates
MannKind (MNKD) came out with a quarterly loss of $0.07 per share versus the Zacks Consensus Estimate of a loss of $0.08. This compares to earnings of $0.03 per share a year ago.
Zacks Investment Research • Nov 5, 2026

Compared to Estimates, MannKind (MNKD) Q3 Earnings: A Look at Key Metrics
Although the revenue and EPS for MannKind (MNKD) give a sense of how its business performed in the quarter ended September 2026, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.
Zacks Investment Research • Nov 6, 2026

MannKind to Report Third Quarter Financial Results and Host Conference Call on November 5, 2026
DANBURY, Conn. and WESTLAKE VILLAGE, Calif., Oct. 29, 2026 (GLOBE NEWSWIRE) -- MannKind Corporation (Nasdaq: MNKD) announced today that it will report third quarter 2026 financial results after market close on Thursday, November 5, 2026.
GlobeNewsWire • Oct 29, 2026

¹ Disclosures

Open an M1 investment account to buy and sell MannKind Corporation commission-free¹. Build wealth for the long term using automated trading and transfers.